LifeVantage Corp

LFVN remains in a Stage 2 advance with medium-term bullish permission, yet the active Post-Parabola Collapse pattern and rejection at the declining short EMAs signal a corrective unwind. Price sits below the 9- and 20-day EMAs and is testing the rising 50-day SMA as support. Immediate entry is unfavorable; waiting for a pullback into the 50-day SMA zone and a clean reclaim of the short EMAs offers a higher-probability bullish engagement.

• ↑Love Biome acquisition expands gut-health offerings in a segment set to grow from $14.4B to $32.4B by 2035.
• ↑MindBody GLP-1 system rollout and nutrigenomics supplements diversify revenue streams.
• ↓Q3 revenue down 25.2% YoY to $43.7M, missing the $48.9M estimate.